Integrated Filing — IndAS



General information about company
Scrip Code 544067
NSE Symbol INNOVACAP
MSEI Symbol NOTLISTED
ISIN INE0DUT01020
Name of company INNOVA CAPTAB LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 07-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment Drugs and Pharmaceutical products
Start date and time of board meeting 07-Aug-2025   15:30:00
End date and time of board meeting 07-Aug-2025   16:35:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3515420000
Other income 44830000
Total income 3560250000
2 Expenses
(a) Cost of materials consumed 2294440000
(b) Purchases of stock-in-trade 50470000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -137530000
(d) Employee benefit expense 390900000
(e) Finance costs 28600000
(f) Depreciation, depletion and amortisation expense 110450000
(f) Other Expenses
1 Power and fuel 93950000 93950000
2 Stores and spares consumed 49370000 49370000
3 Repairs and maintenance 30640000 30640000
4 Packing charges 40380000 40380000
5 Lab consumables 12140000 12140000
6 Legal and professional fee 11970000 11970000
7 CSR expenditure 8330000 8330000
8 Rates, fees and taxes 13470000 13470000
9 Freight charges 18520000 18520000
10 Other expenses 117380000 117380000
Total other expenses 396150000
Total expenses 3133480000
3 Total profit before exceptional items and tax 426770000
4 Exceptional items 0
5 Total profit before tax 426770000
6 Tax expense
7 Current tax 62750000
8 Deferred tax 53870000
9 Total tax expenses 116620000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 310150000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0
16 Total profit (loss) for period 310150000
17 Other comprehensive income net of taxes 40000
18 Total Comprehensive Income for the period 310190000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 572250000
Face value of equity share capital 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 5.42
Diluted earnings (loss) per share from continuing operations 5.42
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 5.42
Diluted earnings (loss) per share from continuing and discontinued operations 5.42
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) The above consolidated financial results of Innova Captab Limited and its subsidiaries Holding and its subsidiaries together referred to as the Group have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013 read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India Regulations 2015 as amended The results for the quarter ended 30 June 2025 are available on the Company website under investor information section and on the stock exchange website The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 07 August 2025 The Board of Directors at their meeting held on 07 August 2025 have approved the above results and taken them on record The statutory auditors of the Company have expressed an unmodified review conclusion on the consolidated financial results for the quarter ended 30 June 2025 The Group comprise the following entities all of which have been incorporated in India n Innova Captab Limited Holding Company n Univentis Medicare Limited Subsidiary Company n Sharon Bio Medicine Limited Subsidiary Company n Univentis Foundation Subsidiary nThe Group has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group nThe figures of the last quarter ended 31 March 2025 as reported in these consolidated financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevent financial year Also the figures upto the end of the third quarter had only been reviewed and not subject to audit n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) The Company has only one reportable segment ie Drugs and pharmaceutical products as per IndAS 108 Operating Segments specified under section 133 of the Companies Act 2013 Accordingly the disclosures as per the listing agreement are not applicable to the group n



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement of defined benefit obligation 90000 90000
Total Amount of items that will not be reclassified to profit and loss 90000
2 Income tax relating to items that will not be reclassified to profit or loss 50000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0
5 Total Other comprehensive income 40000